Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Venous Thromboembolism | 31 | 2023 | 1670 | 3.990 |
Why?
|
Pulmonary Embolism | 34 | 2024 | 2375 | 3.130 |
Why?
|
Anticoagulants | 36 | 2023 | 4599 | 1.950 |
Why?
|
Blood Coagulation | 8 | 2020 | 1127 | 1.330 |
Why?
|
Warfarin | 6 | 2023 | 1496 | 1.320 |
Why?
|
Thrombosis | 8 | 2023 | 2968 | 1.270 |
Why?
|
Heparin | 10 | 2022 | 1637 | 1.230 |
Why?
|
Patient Care Team | 9 | 2020 | 2529 | 1.160 |
Why?
|
Venous Thrombosis | 10 | 2023 | 1238 | 1.130 |
Why?
|
Hemorrhage | 22 | 2023 | 3461 | 1.080 |
Why?
|
Thrombophilia | 2 | 2021 | 305 | 0.790 |
Why?
|
Administration, Oral | 12 | 2023 | 3913 | 0.770 |
Why?
|
Thrombolytic Therapy | 9 | 2023 | 2161 | 0.740 |
Why?
|
African Swine Fever | 1 | 2020 | 7 | 0.740 |
Why?
|
Blood Coagulation Factors | 4 | 2020 | 355 | 0.710 |
Why?
|
Fibrin Fibrinogen Degradation Products | 5 | 2021 | 426 | 0.670 |
Why?
|
Heparin, Low-Molecular-Weight | 5 | 2023 | 339 | 0.650 |
Why?
|
Antithrombins | 1 | 2021 | 304 | 0.620 |
Why?
|
Aftercare | 2 | 2020 | 866 | 0.580 |
Why?
|
Pyridones | 2 | 2020 | 712 | 0.540 |
Why?
|
Neoplasms | 18 | 2023 | 21672 | 0.490 |
Why?
|
Standard of Care | 1 | 2018 | 564 | 0.490 |
Why?
|
Blood Coagulation Disorders | 3 | 2021 | 337 | 0.460 |
Why?
|
Flank Pain | 1 | 2013 | 43 | 0.450 |
Why?
|
Renal Veins | 1 | 2013 | 108 | 0.440 |
Why?
|
Pyrazoles | 3 | 2020 | 1973 | 0.430 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 1356 | 0.420 |
Why?
|
Obesity, Morbid | 1 | 2023 | 1213 | 0.410 |
Why?
|
Partial Thromboplastin Time | 2 | 2021 | 206 | 0.350 |
Why?
|
Patient Compliance | 1 | 2020 | 2684 | 0.340 |
Why?
|
Hospitalization | 5 | 2021 | 10262 | 0.330 |
Why?
|
Practice Guidelines as Topic | 7 | 2021 | 7281 | 0.320 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3132 | 0.310 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3239 | 0.310 |
Why?
|
Peptide Fragments | 1 | 2020 | 5096 | 0.310 |
Why?
|
Thromboembolism | 3 | 2021 | 985 | 0.300 |
Why?
|
Catheterization | 2 | 2020 | 1469 | 0.300 |
Why?
|
Factor VIIa | 1 | 2008 | 101 | 0.300 |
Why?
|
Humans | 94 | 2024 | 744220 | 0.290 |
Why?
|
Hospital Rapid Response Team | 2 | 2018 | 57 | 0.290 |
Why?
|
Critical Illness | 5 | 2021 | 2670 | 0.270 |
Why?
|
Clinical Protocols | 4 | 2020 | 1462 | 0.260 |
Why?
|
Pulmonary Artery | 3 | 2021 | 1912 | 0.260 |
Why?
|
Stress, Physiological | 1 | 2012 | 1404 | 0.260 |
Why?
|
Hematopoietic Cell Growth Factors | 2 | 2022 | 102 | 0.230 |
Why?
|
Delivery of Health Care | 3 | 2019 | 5319 | 0.230 |
Why?
|
Risk Factors | 23 | 2023 | 72280 | 0.210 |
Why?
|
Retrospective Studies | 18 | 2023 | 77426 | 0.200 |
Why?
|
Middle Aged | 36 | 2023 | 213367 | 0.190 |
Why?
|
Micropore Filters | 1 | 2020 | 23 | 0.190 |
Why?
|
Female | 49 | 2023 | 380197 | 0.190 |
Why?
|
Ceruloplasmin | 1 | 2020 | 56 | 0.190 |
Why?
|
Platelet Count | 2 | 2020 | 781 | 0.190 |
Why?
|
Iron Metabolism Disorders | 1 | 2020 | 27 | 0.190 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2021 | 93 | 0.190 |
Why?
|
Consensus | 4 | 2023 | 2958 | 0.190 |
Why?
|
Thrombocytopenia | 4 | 2020 | 1175 | 0.190 |
Why?
|
Pipecolic Acids | 1 | 2021 | 76 | 0.190 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 3611 | 0.190 |
Why?
|
Prothrombin | 1 | 2020 | 185 | 0.180 |
Why?
|
Drug Antagonism | 1 | 2019 | 50 | 0.180 |
Why?
|
Aged | 31 | 2023 | 163253 | 0.180 |
Why?
|
Hirudins | 1 | 2021 | 183 | 0.180 |
Why?
|
Endothelial Cells | 1 | 2012 | 3478 | 0.180 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.180 |
Why?
|
Acute Disease | 8 | 2023 | 7148 | 0.180 |
Why?
|
von Willebrand Disease, Type 1 | 1 | 2019 | 5 | 0.170 |
Why?
|
Risk Assessment | 11 | 2023 | 23337 | 0.170 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2019 | 91 | 0.170 |
Why?
|
Fibrinolytic Agents | 4 | 2023 | 2158 | 0.170 |
Why?
|
Male | 40 | 2023 | 350027 | 0.160 |
Why?
|
Outpatients | 4 | 2018 | 1486 | 0.160 |
Why?
|
Ultrasonography, Doppler | 1 | 2020 | 458 | 0.160 |
Why?
|
Recombinant Proteins | 3 | 2021 | 6612 | 0.160 |
Why?
|
Ambulatory Care | 2 | 2020 | 2708 | 0.150 |
Why?
|
Drug Monitoring | 2 | 2021 | 956 | 0.150 |
Why?
|
Pyrrolidinones | 1 | 2018 | 117 | 0.150 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 252 | 0.150 |
Why?
|
Risk Adjustment | 1 | 2021 | 594 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11493 | 0.150 |
Why?
|
Thrombectomy | 3 | 2017 | 679 | 0.150 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 11732 | 0.150 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2017 | 102 | 0.150 |
Why?
|
Antiphospholipid Syndrome | 1 | 2018 | 173 | 0.140 |
Why?
|
Dextrocardia | 1 | 2016 | 37 | 0.140 |
Why?
|
Hospitals, University | 1 | 2019 | 571 | 0.140 |
Why?
|
Anemia | 3 | 2022 | 1504 | 0.140 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5180 | 0.140 |
Why?
|
Emergency Treatment | 2 | 2018 | 517 | 0.140 |
Why?
|
Adult | 25 | 2024 | 214035 | 0.140 |
Why?
|
Plasma | 1 | 2019 | 575 | 0.130 |
Why?
|
Treatment Outcome | 13 | 2021 | 63119 | 0.130 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2020 | 233 | 0.130 |
Why?
|
Myeloproliferative Disorders | 1 | 2021 | 605 | 0.130 |
Why?
|
Emergency Service, Hospital | 6 | 2019 | 7659 | 0.130 |
Why?
|
History, 19th Century | 1 | 2017 | 720 | 0.120 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1261 | 0.120 |
Why?
|
Patient Transfer | 1 | 2021 | 761 | 0.120 |
Why?
|
Ultrasonography | 2 | 2020 | 5982 | 0.120 |
Why?
|
China | 1 | 2020 | 2247 | 0.120 |
Why?
|
Mass Screening | 1 | 2010 | 5252 | 0.120 |
Why?
|
Aorta | 1 | 2021 | 2061 | 0.110 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4929 | 0.110 |
Why?
|
Quinolines | 1 | 2018 | 730 | 0.110 |
Why?
|
ROC Curve | 1 | 2020 | 3527 | 0.110 |
Why?
|
Drug Interactions | 1 | 2017 | 1458 | 0.110 |
Why?
|
Lower Extremity | 1 | 2020 | 1158 | 0.110 |
Why?
|
Echocardiography | 3 | 2020 | 5103 | 0.110 |
Why?
|
Antibodies, Antinuclear | 1 | 2013 | 326 | 0.110 |
Why?
|
Obesity | 3 | 2023 | 12742 | 0.100 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2013 | 142 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 5221 | 0.100 |
Why?
|
Emergency Medicine | 2 | 2019 | 1207 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1416 | 0.100 |
Why?
|
C-Reactive Protein | 2 | 2020 | 3778 | 0.100 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1176 | 0.100 |
Why?
|
Medical Oncology | 2 | 2020 | 2265 | 0.100 |
Why?
|
Neurodegenerative Diseases | 1 | 2020 | 1062 | 0.100 |
Why?
|
Aged, 80 and over | 9 | 2021 | 57768 | 0.100 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2016 | 582 | 0.100 |
Why?
|
History, 21st Century | 1 | 2017 | 1534 | 0.100 |
Why?
|
Intensive Care Units | 3 | 2021 | 3680 | 0.100 |
Why?
|
Thromboplastin | 1 | 2012 | 291 | 0.100 |
Why?
|
Hypotension | 1 | 2016 | 880 | 0.090 |
Why?
|
Inpatients | 2 | 2021 | 2518 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1772 | 0.090 |
Why?
|
Enoxaparin | 1 | 2012 | 377 | 0.090 |
Why?
|
Pandemics | 5 | 2021 | 8387 | 0.090 |
Why?
|
Occupational Exposure | 1 | 2020 | 1796 | 0.090 |
Why?
|
Headache | 1 | 2017 | 1226 | 0.090 |
Why?
|
Swine | 1 | 2020 | 5940 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2021 | 1831 | 0.090 |
Why?
|
Massachusetts | 2 | 2020 | 8663 | 0.090 |
Why?
|
Factor Xa | 2 | 2020 | 162 | 0.090 |
Why?
|
History, 20th Century | 1 | 2017 | 2739 | 0.090 |
Why?
|
Vena Cava Filters | 3 | 2017 | 252 | 0.080 |
Why?
|
Review Literature as Topic | 2 | 2008 | 336 | 0.080 |
Why?
|
Heart Ventricles | 1 | 2021 | 3820 | 0.080 |
Why?
|
Thalidomide | 1 | 2012 | 890 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2020 | 3528 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2018 | 2147 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3216 | 0.070 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1581 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2018 | 13096 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2020 | 3336 | 0.070 |
Why?
|
Cohort Studies | 7 | 2023 | 40559 | 0.070 |
Why?
|
Cluster Analysis | 1 | 2012 | 2715 | 0.070 |
Why?
|
Antineoplastic Agents | 2 | 2022 | 13668 | 0.070 |
Why?
|
Resource Allocation | 1 | 2008 | 341 | 0.070 |
Why?
|
Dexamethasone | 1 | 2012 | 1948 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2019 | 13990 | 0.060 |
Why?
|
Shock | 1 | 2008 | 318 | 0.060 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12961 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14726 | 0.060 |
Why?
|
Recurrence | 3 | 2023 | 8343 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9230 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2022 | 5034 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 9960 | 0.060 |
Why?
|
Evidence-Based Practice | 1 | 2008 | 500 | 0.060 |
Why?
|
Safety | 1 | 2008 | 1185 | 0.050 |
Why?
|
Genotype | 2 | 2021 | 12956 | 0.050 |
Why?
|
Pyridines | 1 | 2014 | 2822 | 0.050 |
Why?
|
Lung | 1 | 2021 | 9852 | 0.050 |
Why?
|
Sex Characteristics | 2 | 2023 | 2586 | 0.050 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2013 | 2103 | 0.050 |
Why?
|
Chelation Therapy | 1 | 2020 | 67 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11368 | 0.050 |
Why?
|
Surge Capacity | 1 | 2020 | 42 | 0.050 |
Why?
|
Cause of Death | 2 | 2021 | 3584 | 0.050 |
Why?
|
Censuses | 1 | 2021 | 200 | 0.050 |
Why?
|
Catheterization, Central Venous | 1 | 2005 | 513 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39045 | 0.040 |
Why?
|
Skin Diseases | 1 | 2008 | 1065 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9981 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 13885 | 0.040 |
Why?
|
Respiration, Artificial | 2 | 2021 | 2569 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17449 | 0.040 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 1 | 2020 | 141 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2020 | 104 | 0.040 |
Why?
|
Mitral Valve | 1 | 2008 | 1490 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 196 | 0.040 |
Why?
|
Prospective Studies | 4 | 2020 | 53280 | 0.040 |
Why?
|
Iodine | 1 | 2021 | 286 | 0.040 |
Why?
|
Heart Failure | 1 | 2022 | 10905 | 0.040 |
Why?
|
Unconsciousness | 1 | 2020 | 263 | 0.040 |
Why?
|
United States | 6 | 2023 | 69867 | 0.040 |
Why?
|
Pulmonary Circulation | 1 | 2021 | 739 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 681 | 0.040 |
Why?
|
Patient Care Management | 1 | 2021 | 306 | 0.040 |
Why?
|
Equipment Failure Analysis | 1 | 2020 | 868 | 0.040 |
Why?
|
Ferritins | 1 | 2020 | 590 | 0.040 |
Why?
|
Blood Coagulation Tests | 1 | 2019 | 263 | 0.040 |
Why?
|
Age Factors | 1 | 2014 | 18367 | 0.040 |
Why?
|
Bone Marrow Examination | 1 | 2017 | 157 | 0.040 |
Why?
|
Mortality | 2 | 2021 | 2864 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 15161 | 0.040 |
Why?
|
Length of Stay | 2 | 2021 | 6308 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2017 | 20123 | 0.040 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2017 | 188 | 0.040 |
Why?
|
North America | 1 | 2020 | 1250 | 0.040 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2008 | 1534 | 0.040 |
Why?
|
Expert Testimony | 1 | 2019 | 356 | 0.040 |
Why?
|
Group Processes | 1 | 2018 | 225 | 0.040 |
Why?
|
Anemia, Hemolytic | 1 | 2017 | 168 | 0.040 |
Why?
|
Ethanol | 1 | 2023 | 1342 | 0.040 |
Why?
|
Cerebral Veins | 1 | 2017 | 156 | 0.040 |
Why?
|
Academic Medical Centers | 2 | 2017 | 2759 | 0.040 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 412 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8090 | 0.030 |
Why?
|
Hemostatics | 1 | 2019 | 229 | 0.030 |
Why?
|
Angiography | 1 | 2022 | 1638 | 0.030 |
Why?
|
Embolectomy | 1 | 2016 | 120 | 0.030 |
Why?
|
Prognosis | 3 | 2023 | 29050 | 0.030 |
Why?
|
Hospital Bed Capacity | 1 | 2017 | 214 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15538 | 0.030 |
Why?
|
Catheterization, Swan-Ganz | 1 | 2016 | 86 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2309 | 0.030 |
Why?
|
Incidental Findings | 1 | 2020 | 689 | 0.030 |
Why?
|
von Willebrand Factor | 1 | 2019 | 669 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10387 | 0.030 |
Why?
|
Medicare | 2 | 2023 | 6566 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2017 | 537 | 0.030 |
Why?
|
Incidence | 1 | 2012 | 20945 | 0.030 |
Why?
|
Intracranial Hemorrhages | 1 | 2020 | 855 | 0.030 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 840 | 0.030 |
Why?
|
Disease Management | 1 | 2005 | 2458 | 0.030 |
Why?
|
Pulmonary Medicine | 1 | 2016 | 213 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2018 | 825 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1071 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 942 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 7730 | 0.030 |
Why?
|
Drug Approval | 1 | 2020 | 741 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 574 | 0.030 |
Why?
|
Hematology | 1 | 2016 | 221 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10250 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2023 | 3506 | 0.030 |
Why?
|
Postoperative Hemorrhage | 1 | 2016 | 412 | 0.030 |
Why?
|
Splenectomy | 1 | 2013 | 395 | 0.030 |
Why?
|
Drug Costs | 1 | 2020 | 1105 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1583 | 0.030 |
Why?
|
Hospitals, General | 1 | 2016 | 749 | 0.030 |
Why?
|
Spleen | 1 | 2017 | 2361 | 0.020 |
Why?
|
Autoantibodies | 1 | 2020 | 2038 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2017 | 1062 | 0.020 |
Why?
|
Critical Care | 1 | 2024 | 2644 | 0.020 |
Why?
|
Cell-Derived Microparticles | 1 | 2012 | 168 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 950 | 0.020 |
Why?
|
Vision Disorders | 1 | 2017 | 1059 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1692 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2213 | 0.020 |
Why?
|
Pregnancy | 2 | 2023 | 29142 | 0.020 |
Why?
|
Thoracic Surgery | 1 | 2016 | 719 | 0.020 |
Why?
|
Mutation | 3 | 2021 | 29784 | 0.020 |
Why?
|
Medicine | 1 | 2017 | 946 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9311 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10949 | 0.020 |
Why?
|
Animals | 1 | 2020 | 168788 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 2987 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 40063 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5300 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3250 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2021 | 5316 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 602 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10396 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12781 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1531 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6546 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 783 | 0.020 |
Why?
|
Child | 2 | 2024 | 77679 | 0.020 |
Why?
|
Cardiology | 1 | 2016 | 1668 | 0.020 |
Why?
|
Prevalence | 1 | 2021 | 15226 | 0.020 |
Why?
|
Necrosis | 1 | 2008 | 1643 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2013 | 2108 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9849 | 0.010 |
Why?
|
Bone Marrow | 1 | 2013 | 2944 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11007 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12244 | 0.010 |
Why?
|
Brain | 2 | 2020 | 26413 | 0.010 |
Why?
|
Radiology | 1 | 2016 | 2099 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 12805 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1404 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 6535 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10634 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 56436 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2727 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2211 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2008 | 2538 | 0.010 |
Why?
|
Societies, Medical | 1 | 2008 | 3741 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 7908 | 0.010 |
Why?
|
Decision Making | 1 | 2008 | 3888 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 35423 | 0.010 |
Why?
|
Research Design | 1 | 2008 | 5987 | 0.010 |
Why?
|